<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">24237940</PMID>
<DateCompleted>
<Year>2015</Year>
<Month>05</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>05</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1478-3231</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>34</Volume>
<Issue>8</Issue>
<PubDate>
<Year>2014</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Liver international : official journal of the International Association for the Study of the Liver</Title>
<ISOAbbreviation>Liver Int.</ISOAbbreviation>
</Journal>
<ArticleTitle>Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study.</ArticleTitle>
<Pagination>
<MedlinePgn>1267-77</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/liv.12385</ELocationID>
<Abstract>
<AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">Type 2 diabetes is an established risk factor for the presence and progression of fatty liver. Little is known about the distributions and correlates of hepatic non-invasive biomarkers in community-based populations with diabetes, unselected for liver disease. We aimed to identify the distribution of, and metabolic risk factors associated with serum cytokeratin-18 (CK18) and the Enhanced Liver Fibrosis score (ELF), in a large, representative cohort of people with type 2 diabetes (the Edinburgh Type 2 Diabetes Study, ET2DS).</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Nine hundred and thirty-nine ET2DS participants, aged 60-74 years underwent physical examination including ultrasound for assessment of liver fat. Representative subgroups were assessed for markers of chronic liver disease (CK18 and ELF).</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">CK18 values ranged from 29-993 U/L (median 102, IQR 76-137 U/L) and ELF scores ranged from 6.9-11.6 (mean 8.9, SD 0.8). Statistically significant associations were found between both biomarkers and a number of metabolic risk factors. Neither CK18 nor ELF was consistently or strongly associated with established hepatic risk factors (alcohol excess, hepatotoxic medication use and positive immunology titres).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We identified the distribution of CK18 and ELF in a large cohort of older people with type 2 diabetes and showed that these markers are associated with an adverse metabolic risk factor profile, although much of the variation in biomarkers remained unexplained. Prospective studies are required to determine the extent to which CK18 and/or ELF predict the development of symptomatic liver disease and to identify additional risk factors which may influence the development of advanced liver disease in people with type 2 diabetes.</AbstractText>
<CopyrightInformation>Â© 2013 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Morling</LastName>
<ForeName>Joanne R</ForeName>
<Initials>JR</Initials>
<AffiliationInfo>
<Affiliation>Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fallowfield</LastName>
<ForeName>Jonathan A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Williamson</LastName>
<ForeName>Rachel M</ForeName>
<Initials>RM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Nee</LastName>
<ForeName>Lisa D</ForeName>
<Initials>LD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jackson</LastName>
<ForeName>Andrew P</ForeName>
<Initials>AP</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Glancy</LastName>
<ForeName>Stephen</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Reynolds</LastName>
<ForeName>Rebecca M</ForeName>
<Initials>RM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hayes</LastName>
<ForeName>Peter C</ForeName>
<Initials>PC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Guha</LastName>
<ForeName>Indra N</ForeName>
<Initials>IN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Strachan</LastName>
<ForeName>Mark W J</ForeName>
<Initials>MW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Price</LastName>
<ForeName>Jackie F</ForeName>
<Initials>JF</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>G84/6205</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>10/0003985</GrantID>
<Agency>Diabetes UK</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>G0500877</GrantID>
<Agency>Medical Research Council</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>CZB/4/582</GrantID>
<Agency>Chief Scientist Office</Agency>
<Country>United Kingdom</Country>
</Grant>
<Grant>
<GrantID>CZG/2/478</GrantID>
<Agency>Chief Scientist Office</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>12</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Liver Int</MedlineTA>
<NlmUniqueID>101160857</NlmUniqueID>
<ISSNLinking>1478-3223</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053538">Keratin-18</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015415">Biomarkers</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003924">Diabetes Mellitus, Type 2</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005234">Fatty Liver</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D053538">Keratin-18</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008103">Liver Cirrhosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" Type="Geographic" UI="D012606">Scotland</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM">
<Keyword MajorTopicYN="N">cytokeratin-18</Keyword>
<Keyword MajorTopicYN="N">enhanced liver fibrosis score</Keyword>
<Keyword MajorTopicYN="N">fatty liver disease</Keyword>
<Keyword MajorTopicYN="N">non-invasive hepatic biomarkers</Keyword>
<Keyword MajorTopicYN="N">type 2 diabetes mellitus</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2013</Year>
<Month>07</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2013</Year>
<Month>11</Month>
<Day>09</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2013</Year>
<Month>11</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2013</Year>
<Month>11</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2015</Year>
<Month>5</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">24237940</ArticleId>
<ArticleId IdType="doi">10.1111/liv.12385</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>